+

WO2006109196A3 - Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc - Google Patents

Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc Download PDF

Info

Publication number
WO2006109196A3
WO2006109196A3 PCT/IB2006/001668 IB2006001668W WO2006109196A3 WO 2006109196 A3 WO2006109196 A3 WO 2006109196A3 IB 2006001668 W IB2006001668 W IB 2006001668W WO 2006109196 A3 WO2006109196 A3 WO 2006109196A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
compositions
hepatitis
virus
identification
Prior art date
Application number
PCT/IB2006/001668
Other languages
English (en)
Other versions
WO2006109196A2 (fr
Inventor
Matti Sallberg
Lars Frelin
Original Assignee
Tripep Ab
Matti Sallberg
Lars Frelin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/003736 external-priority patent/WO2006021896A2/fr
Application filed by Tripep Ab, Matti Sallberg, Lars Frelin filed Critical Tripep Ab
Publication of WO2006109196A2 publication Critical patent/WO2006109196A2/fr
Publication of WO2006109196A3 publication Critical patent/WO2006109196A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention porte sur la découverte de nouvelles compositions NS3/4A présentant de meilleures capacités d'expression. Les réalisations de l'invention comprennent des compositions NS3/4A optimisées par le codon et des compositions ayant le réplicon du virus de la forêt de Semliki. D'autres réalisations comprennent des organismes transgéniques contenant ces compositions NS3/4A, sur les méthodes d'utilisation de ces souris transgéniques pour cribler et raffiner des médicaments et sur les médicaments raffinés selon ses méthodes. Des réalisations additionnelles comprennent des molécules dépendant de l'activité des protéases et qui peuvent indiquer la présence ou l'absence d'un inhibiteur de protéases.
PCT/IB2006/001668 2005-02-04 2006-02-03 Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc WO2006109196A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64997505P 2005-02-04 2005-02-04
US60/649,975 2005-02-04
IBPCT/IB2005/003736 2005-08-26
PCT/IB2005/003736 WO2006021896A2 (fr) 2004-08-27 2005-08-26 Modele de souris transgenique du virus de l'hepatite c (hcv) et identification de therapeutiques du hcv
US74036205P 2005-11-28 2005-11-28
US60/740,362 2005-11-28

Publications (2)

Publication Number Publication Date
WO2006109196A2 WO2006109196A2 (fr) 2006-10-19
WO2006109196A3 true WO2006109196A3 (fr) 2007-03-15

Family

ID=37025261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001668 WO2006109196A2 (fr) 2005-02-04 2006-02-03 Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc

Country Status (1)

Country Link
WO (1) WO2006109196A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150899A1 (fr) * 2007-05-29 2008-12-11 Emory University Thérapies combinées pour le traitement du cancer et des maladies inflammatoires
WO2011161644A1 (fr) 2010-06-24 2011-12-29 Panmed Ltd. Traitement de maladies associées au virus de l'hépatite c utilisant de l'hydroxychloroquine ou de l'hydroxychloroquine associée à un agent antiviral
WO2012038950A1 (fr) 2010-09-20 2012-03-29 Ramot At Tel-Aviv University Ltd. Complexes de toxine activables comprenant un peptide inhibiteur clivable
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
RU2012112128A (ru) * 2012-03-29 2013-10-10 Холин Максим Николаевич ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
CN117085007B (zh) * 2023-09-28 2024-12-20 南通大学 冬凌草甲素在制备预防或治疗雄性少弱精症药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038888A2 (fr) * 1998-02-02 1999-08-05 Istituto Di Ricerche Di Biologia Molecolare Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
WO1999061039A2 (fr) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle composition de modulation de la mort cellulaire ischemique
WO2001035959A1 (fr) * 1999-11-18 2001-05-25 Astrazeneca Ab Utilisation de derives de thiazole pour traiter/prevenir les troubles induits par la kinase p38
JP2004000179A (ja) * 2002-03-29 2004-01-08 Toray Ind Inc Ｃ型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法
US20040229936A1 (en) * 2003-04-02 2004-11-18 Hsing-Pang Hsieh Treatment of hepatitis C virus infection with sesquiterpene lactones

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038888A2 (fr) * 1998-02-02 1999-08-05 Istituto Di Ricerche Di Biologia Molecolare Inhibiteurs peptidiques de l'activite de la serine protease associee a la proteine ns53 de vhc, leurs utilisations correspondantes et leur procede de production
WO1999061039A2 (fr) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle composition de modulation de la mort cellulaire ischemique
WO2001035959A1 (fr) * 1999-11-18 2001-05-25 Astrazeneca Ab Utilisation de derives de thiazole pour traiter/prevenir les troubles induits par la kinase p38
JP2004000179A (ja) * 2002-03-29 2004-01-08 Toray Ind Inc Ｃ型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法
US20040229936A1 (en) * 2003-04-02 2004-11-18 Hsing-Pang Hsieh Treatment of hepatitis C virus infection with sesquiterpene lactones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRELIN L ET AL: "Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 11, no. 6, 2004, pages 522 - 533, XP002285893, ISSN: 0969-7128 *
LERAT HERVE ET AL: "Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus", GASTROENTEROLOGY, vol. 122, no. 2, February 2002 (2002-02-01), pages 352 - 365, XP002372198, ISSN: 0016-5085 *
MAJUMDER M ET AL: "Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 555, no. 3, 18 December 2003 (2003-12-18), pages 528 - 532, XP004481044, ISSN: 0014-5793 *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Also Published As

Publication number Publication date
WO2006109196A2 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
WO2006109196A3 (fr) Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
Venkatraman Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections
Brecher et al. The flavivirus protease as a target for drug discovery
NZ593808A (en) Inhibitors of hcv ns5a
Hoenen et al. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
DE602005015834D1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2008051477A3 (fr) Inhibiteurs de la protéase hcv ns3
WO2006130626A3 (fr) Procede de modulation de l'activite de la protease du vhc au moyen d'un nouvel inhibiteur de la protease du vhc aux fins de la reduction de la duree du traitement
PT1268519E (pt) Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
WO2007016476A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
WO2005087721A3 (fr) Nouveaux composes en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
WO2007140200A3 (fr) Inhibiteurs de la ns5b du vch à base d'indolobenzazépine fusionnée au cyclopropyle
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
MY142240A (en) Hcv ns3 protease inhibitors
WO2005087731A8 (fr) Composes soufres en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
WO2006119061A3 (fr) Inhibiteurs de la protease ns3 du vhc
NO20063205L (no) Inhibitorer for hepatitt C-virus NS3/NS4A-serinprotease
Meanwell 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing hepatitis C virus infection with direct-acting antiviral agents: the arc of a medicinal chemistry triumph
ATE434621T1 (de) Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
DE602005015452D1 (de) Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
MY164469A (en) Hcv ns3 protease inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06765563

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06765563

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6765563

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载